Storia in 2 fonti

Rush to PCSK9 Inhibitor Pretreatment Disappoints in Acute MI Trial

Quick lipid lowering did not translate to clinical benefit at 1 year

Raccontata da

healio.com

medpagetoday.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

medpagetoday.comStai leggendo1 g fa

Rush to PCSK9 Inhibitor Pretreatment Disappoints in Acute MI Trial

Quick lipid lowering did not translate to clinical benefit at 1 year

originale

healio.com1 g fa

Evolocumab before PCI for acute MI improves LDL control

MUNICH — Early administration of evolocumab prior to PCI for acute MI significantly improved patients’ chances of meeting guideline-recommended LDL goals by 1 year, but did not impact clinical outcomes vs. standard…

Leggi questa versione → originale

Timeline cronologica

sabato 29 agosto 2026·healio.com
Evolocumab before PCI for acute MI improves LDL control
MUNICH — Early administration of evolocumab prior to PCI for acute MI significantly improved patients’ chances of meeting guideline-recommended LDL goals by 1 year, but did not…
sabato 29 agosto 2026·medpagetoday.com
Rush to PCSK9 Inhibitor Pretreatment Disappoints in Acute MI Trial
Quick lipid lowering did not translate to clinical benefit at 1 year